Angiotensin-receptor neprilysin inhibitor LCZ696; A novel therapy for heart failure

Mohammad B.I.¹ , Hadi N.R.² , Singh R.B. ³ , Shastun S. ⁴ , Sharmanov T.⁵ , Tazhibayev S.⁵ , Gumarova L.⁶

World Heart Journal

1

Английский

13-16

Опубликовано

Внешняя ссылка

7

2015

• ¹ College of Pharmacy, University of Al Qadisiyah, Iraq
• ² Department of Pharmacology, Kufa University, Najaf, Iraq
• ³ Halberg Hospital and Research Institute, Moradabad, India
• ⁴ People’s Friendship University of Russia, Moscow, Russian Federation
• ⁵ Kazakh Academy of Nutrition, Almaty, Kazakhstan
• ⁶ Al-Farabi Kazakh National University, Almaty, Kazakhstan

angiotensin receptor; carnitine; enalapril; eplerenone; hydralazine plus isosorbide dinitrate; membrane metalloendopeptidase; omega 3 fatty acid; sacubitril plus valsartan; ubidecarenone; valsartan; Article; atrial fibrillation; cardiovascular mortality; cardiovascular risk; clinical feature; diabetes mellitus; drug efficacy; drug mechanism; food and drug administration; heart ejection fraction; heart failure; heart left ventricle ejection fraction; heart left ventricle wall; heart volume; hospitalization; human; kidney function; morbidity; New York Heart Association class; nutritional deficiency; phase 2 clinical trial (topic); randomized controlled trial (topic); renin angiotensin aldosterone system; systolic blood pressure

19.10.2018

19.10.2018

https://repository.rudn.ru/ru/records/article/record/4800/